Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel… Read more
Eusol Biotech Co.,Ltd. (6652) - Net Assets
Latest net assets as of June 2025: NT$347.48 Million TWD
Based on the latest financial reports, Eusol Biotech Co.,Ltd. (6652) has net assets worth NT$347.48 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$355.58 Million) and total liabilities (NT$8.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$347.48 Million |
| % of Total Assets | 97.72% |
| Annual Growth Rate | 0.25% |
| 5-Year Change | 42.07% |
| 10-Year Change | N/A |
| Growth Volatility | 32.35 |
Eusol Biotech Co.,Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Eusol Biotech Co.,Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eusol Biotech Co.,Ltd. (2019–2024)
The table below shows the annual net assets of Eusol Biotech Co.,Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$370.43 Million | -7.62% |
| 2023-12-31 | NT$400.98 Million | -4.94% |
| 2022-12-31 | NT$421.82 Million | -2.81% |
| 2021-12-31 | NT$434.03 Million | +66.46% |
| 2020-12-31 | NT$260.75 Million | -28.73% |
| 2019-12-31 | NT$365.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eusol Biotech Co.,Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30831000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.37 Billion | 369.84% |
| Other Comprehensive Income | NT$1.51 Million | 0.41% |
| Other Components | NT$550.00 Million | 148.47% |
| Total Equity | NT$370.43 Million | 100.00% |
Eusol Biotech Co.,Ltd. Competitors by Market Cap
The table below lists competitors of Eusol Biotech Co.,Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Impero AS
CO:IMPERO
|
$12.16 Million |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
$12.16 Million |
|
Amanah Leasing Public Company Limited
BK:AMANAH
|
$12.17 Million |
|
TRP_AESTHETIC CONNECT
BK:TRP
|
$12.17 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$12.16 Million |
|
Mercer Bancorp Inc.
OTCGREY:MSBB
|
$12.16 Million |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
$12.16 Million |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
$12.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eusol Biotech Co.,Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 400,982,000 to 370,434,000, a change of -30,548,000 (-7.6%).
- Net loss of 30,548,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-30.55 Million | -8.25% |
| Total Change | NT$- | -7.62% |
Book Value vs Market Value Analysis
This analysis compares Eusol Biotech Co.,Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.05x to 2.22x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$2.93 | NT$6.00 | x |
| 2020-12-31 | NT$2.09 | NT$6.00 | x |
| 2021-12-31 | NT$3.24 | NT$6.00 | x |
| 2022-12-31 | NT$3.08 | NT$6.00 | x |
| 2023-12-31 | NT$2.95 | NT$6.00 | x |
| 2024-12-31 | NT$2.70 | NT$6.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eusol Biotech Co.,Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-8.25%) is above the historical average (-21.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -29.32% | 0.00% | 0.00x | 1.07x | NT$-143.84 Million |
| 2020 | -43.63% | 0.00% | 0.00x | 1.08x | NT$-139.84 Million |
| 2021 | -28.41% | 0.00% | 0.00x | 1.05x | NT$-166.71 Million |
| 2022 | -4.34% | 0.00% | 0.00x | 1.05x | NT$-60.49 Million |
| 2023 | -12.87% | 0.00% | 0.00x | 1.02x | NT$-91.71 Million |
| 2024 | -8.25% | 0.00% | 0.00x | 1.02x | NT$-67.59 Million |
Industry Comparison
This section compares Eusol Biotech Co.,Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eusol Biotech Co.,Ltd. (6652) | NT$347.48 Million | -29.32% | 0.02x | $12.16 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |